Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Urology
Title   A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-muscle invasive Bladder Cancer
Summary   NYU Winthrop Hospital Department of Urology is conducting this clinical research study for men and women ages 18 and older who have biopsy proven Non-muscle invasive Bladder Cancer.
Description   This study will evaluate the safety and efficacy of ALT-803 and BCG combination therapy in treating patients with Non-muscle Invasive Bladder Cancer (Bladder Cancer that has not spread into the muscles of the bladder). Participants will be randomly assigned to receive ALT-803 and BCG therapy or BCG therapy alone. The drugs will be inserted into the bladder through a catheter (a tube inserted into the bladder).
IRB Number   15020
Inclusion/Notes   To be eligible for this clinical research study you must:
- Have biopsy confirmation of high grade, high-risk, Non-muscle Invasive Bladder Cancer of the transitional cell carcinoma subtype
- Have adequate heart, lung, liver and kidney function
Principal Name   Aaron Katz, MD
Contact Name   Kaitlin Kosinski, MS
Email   urologyresearch@nyuwinthrop.org
Phone   516-535-1900